CGCharlotte van Ginkel

Charlotte van Ginkel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charlotte van Ginkel has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Carry-over effects in GAG therapy efficacy trial solution for bladder pain syndrome/interstitial cystitis (GETSBI study): an interim analysis

    by Charlotte van Ginkel, J M M Groenewoud, Thomas J Hoogeboom, John Heesakkers, Frank Martens, Dick Janssen

    Objectives The double blind, multicentre, randomised, placebo-controlled GAG-therapy Efficacy Trial Solution for Bladder pain syndrome/Interstitial cystitis (GETSBI) study aims to evaluate the efficacy of intravesical glycosaminoglycans therapy with hyaluronic acid and chondroitin sulfate in symptomatic bladder pain syndrome/interstitial cystitis (BPS/IC) patients with Hunner lesions. This trial encompasses multiple methodologies, including a standard randomised controlled trial (RCT), a cross-over trial and an N-of-1 trial. An N-of-1 trial is a multiple crossover trial, usually randomised and often blinded, conducted in a single patient (1). The N-of-1 methodology is, however, only valid under the condition that there is no carry-over effect, meaning a carry-over of effect from an a-priori intervention period into the placebo period. Therefore, it is important to examine any potential carry-over effects to determine the validity of the study protocol concerning the N-of-1 trial part and thereby justifying recruitment. Design Interim analysis for potential carry-over effects. Setting Secondary care, 21 participants. Participants 21 participants, participants concluded part one from the GETSBI study at time of this analysis (October 2023). Outcome measure The primary outcome of the study is the change from baseline in pain intensity, measured by visual analogue scale (VAS) pain. To assess for carry-over effects, the placebo responses on VAS pain were compared between groups with (n=10) and without (n=11) potential carry-over effects. The threshold for a clinically relevant carry-over effect was set at a difference on VAS pain >0.50 points. Data were analysed using descriptive statistics, T-tests, effect sizes and 95% CI. Statistical significance was set at α=0.05. Results The mean baseline VAS pain did not differ (p=0.12) between group A (n=10, VAS 7.52, SD=0.52) and group B (n=11, VAS 6.02, SD=2.47). The mean placebo responses on VAS pain for groups A and B were 0.97 (SD=1.85) and 1.47 (SD=1.81), respectively. The mean carry-over effect was 0.50 (SD=1.83), which was not statistically significant with a 95% CI of −1.17 to 2.17 and p=0.5369. Conclusions This interim analysis shows that an N-of-1 trial probably will be feasible for evaluating non-curative treatment efficacy in chronic disease using only half the patients as are required for a classic RCT. Future analysis will provide a direct comparison of outcomes between the RCT, crossover and the N-of-1 part for a complete evaluation. Trial registration number ClinicalTrials.gov, NCT05518864 (GETSBI study).


  • Open Access

    Hyaluronic acid: Function and location in the urothelial barrier for bladder pain syndrome/interstitial cystitis, an in vitro study

    by Charlotte J. van Ginkel, Cléo D.M. Baars, Dorien M. Tiemessen, Cornelius F.J. Jansen, Frank M.J. Martens, Jack A. Schalken, Dick A.W. Janssen

    Disruption of the glycosaminoglycan (GAG)-layer and urothelial barrier is an important aspect of the pathophysiology of bladder pain syndrome/ interstitial cystitis. Intravesical hyaluronic acid (HA) is often used in treatments for IC/BPS, however the role in the urothelial barrier is unknown. This study aims to clarify the location and functional contribution of HA in the urothelium, using an in vitro model. Immunohistochemistry was performed on human and porcine biopsies and on porcine cell cultures to evaluate the location of HA. Functional contribution was assessed through transepithelial electrical resistance measurements and the effects on gene expression in a differentiated primary porcine urothelial cell model. HA was found throughout in the urothelium and most abundant around the basal layer. Digestion of HA increased impermeability of the urothelium, contrasting with the effect of protamine sulfate (PS). After HA digestion, quantitative PCR analysis revealed upregulation of HA-synthesizing gene (HAS3) and the inflammatory marker (IL8). Treatment with HA and/or chondroitin sulfate therapy in undamaged cells upregulated genes related to GAG synthesis, barrier markers and inflammation. In PS-damaged cells, GAG therapy only upregulated genes associated with HA synthesis and inflammation, without affecting barrier recovery speed. These results emphasize the interaction of HA on urothelial cell inflammation and barrier repair physiology. HA seems to not directly restore the urothelial luminal GAG layer but influences barrier integrity through its interactions with urothelial cells.


  • Open Access

    Quality of Life and Treatment Modalities in Patients with Interstitial Cystitis: The Patients’ Perspective

    by Charlotte van Ginkel, Frank Martens, Mathilde Scholtes, John Heesakkers, Dick A. W. Janssen

    Background: Quality of life (QoL)-based outcomes are hardly incorporated into interstitial cystitis/bladder pain syndrome (IC/BPS) guidelines, because studies are limited and outdated. Therefore, guidelines might not reflect the current clinical situation accurately. Secondly, guidelines suggest using a multimodal approach for BPS/IC management, but data on the patient-perceived efficacy of these therapies are limited. The aim of this study is to investigate the perception of IC/BPS patients of their QoL, to determine which treatments they have received, and to examine how they evaluate the efficacy of these various (alternative) therapies. Methods: A quantitative retrospective database evaluation was performed, with data from an existing IC/BPS patient survey (n = 217) that was conducted in 2021. This survey contained QoL data based on validated questionnaires such as EQ-5D 5L. Results: The QoL of patients is affected significantly by IC/BPS. This is evident from the various affected domains on the EQ-5D 5L. The symptom severity was negatively affected by a delay in diagnosis, and there were clear differences in QoL domains between females and males. Secondly, coagulation therapy and intravesical glycosaminoglycan (GAG) therapy were most appreciated by patients. Other (alternative) treatments were commonly utilized, although some had doubtful results and high discontinuation rates. Conclusion: QoL is considerably impaired in IC/BPS patients. The diverse responses and adherence to various treatments warrant a personalized approach (phenotype-oriented therapy). To achieve QoL improvement, it is important to incorporate the patient’s perspective in treatment guidelines.


  • Open Access

    Quality of Life and Treatment Modalities in Patients with Interstitial Cystitis: A Patients Perspective

    by Charlotte van Ginkel, Frank Martens, Mathilde Scholtes, John Heesakkers, Dick Aw Janssen

    Background: Quality of life (QoL) in IC/BPS patients is an evidence gap in guidelines, because studies are limited and outdated. Therefore, guidelines might not reflect the current situation accurately, and no possible improvements in QoL of these patients. Secondly, guidelines suggest multimodal approach in therapy, however unknown is how the efficacy of these therapies are perceived by the patient themselves. The aim of this study is to investigate the perception of IC/BPS patients on their QoL and to determine which treatments they received and how they evaluate the efficacy of these various (alternative) therapies.Methods: Quantitative retrospective database study in IC/BPS patients, compiled of existing patient survey data (n=217) from July 2021. Results: The QoL of patients is affected significantly by IC/BPS. This is evident from the substantial self-reported impact by patients, the various affected domains on EQ-5D 5L. The QoL was not negatively affected by delayed diagnosis, but there were differences between female and males. Secondly, there was the wide array of (alternative) treatments utilized, although some have doubtful results and high dropout rates. Conclusion: QoL is considerably impaired in IC/BPS patients. Coagulation therapy and intravesical GAG therapy were most appreciated treatments. The diverse responses and adherence to various treatments warrant a personalized approach (phenotype-oriented therapy). To achieve improvement in the QoL, it is important to incorporate the patient’s perspective in treatment guidelines.

  • Open Access

    The urothelial barrier in interstitial cystitis/bladder pain syndrome: its form and function, an overview of preclinical models

    by Charlotte van Ginkel, Robert E. Hurst, Dick Janssen

    Purpose of review: Investigating bladder pain syndrome/interstitial cystitis (IC/BPS) preclinically is challenging. Various research models have been used to mimic the urothelial barrier closely and replicate the disease. The aim of this review is to discuss preclinical research related to the urothelial barrier in context of IC/BPS. Recent findings: In vivo models mimic IC/BPS mainly with toxic substances in the urine, with protaminesulfate and proteoglycan deglycolysation resembling a temporary impaired barrier as seen in IC/BPS. This temporary increased permeability has also been found in vitro models. Glycosaminoglycan replenishment therapy has been described, in vivo and in vitro, to protect and enhance recover properties of the urothelium. The roles of immune and neurogenic factors in the pathogenesis of IC/BPS remains relatively understudied. Summary: Preclinical studies provide opportunities to identify the involvement of specific pathologic pathways in IC/BPS. For further research is warranted to elucidate the primary or secondary role of permeability, together with inflammatory and neurogenic causes of the disease.


  • Open Access

    The Burden of Urinary Tract Infections on Quality of Life and Healthcare in Patients with Interstitial Cystitis

    by Cléo Baars, Charlotte van Ginkel, John Heesakkers, Mathilde Scholtes, Frank Martens, Dick Janssen

    Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) patients are more susceptible to urinary tract infections (UTIs), likely worsening pre-existing symptoms. However, this receives limited attention in guidelines. This study aimed to explore the burden of UTIs on IC/BPS patients’ quality of life and their healthcare. Methods: Two quantitative retrospective database studies were conducted in cystoscopically proven IC/BPS patients: one compiled existing patient survey data (n = 217) from July 2021 to examine physical and emotional UTI burden, and the other used a patient file database (n = 100) from January 2020 to May 2022, focusing on UTI prevalence, healthcare use, urine cultures and antibiotic resistance. Results: A delay in diagnosis was seen in 70% of patients, due to doctors confusing IC/BPS symptoms with UTIs. The UTI prevalence was over 50%; these patients also report anxiety for new UTIs (70%) and worsening of IC/BPS symptoms (60%). Additionally, for UTI+ patients, healthcare consumption was significantly increased in both studies. Antibiotic resistance (80% of cultures) and prophylactic antibiotic use were common. Conclusions: These findings highlight the burden of UTIs on quality of life in IC/BPS patients and the healthcare system. These results emphasize the need for improved UTI guidelines concerning diagnosis, management and prevention for IC/BPS patients to improve quality of life and care.


  • Open Access

    Study protocol of a multicentre double-blind RCT, comparing a traditional RCT with an aggregated N-of-1 trial: GAG therapy Efficacy Trial Solution for Bladder pain syndrome/Interstitial cystitis (GETSBI study)

    by Charlotte van Ginkel, Cléo Baars, John Heesakkers, Frank Martens, Dick Janssen

    Introduction Obtaining level 1 evidence on efficacy of glycosaminoglycan (GAG) therapy is difficult, due to low incidence of bladder pain syndrome/interstitial cystitis (BPS/IC) and heterogeneous symptoms experienced by patients with BPS/IC. Currently, because of a lack of high-grade evidence, the recommendation for applying GAG therapy in most guidelines is ‘low grade’. An aggregated N-of-1 trial is a multicrossover design that yields similar level 1 evidence as a traditional randomised controlled trial (RCT), while requiring far less patients. The goal of this study is to investigate the efficacy of intravesical GAG therapy (Ialuril) for patients with BPS/IC with Hunner lesions using a dual RCT and aggregated N-of-1 trial design to obtain level 1 evidence. Methods and analysis The GETSBI study is a double-blind multidesign multicentre randomised placebo-controlled study to assess the short-term and long-term efficacy of hyaluronic acid (1.6%) + chondroitin sulfate (2%) therapy (Ialuril Prefill, IBSA, Goodlife) in patients with symptomatic BPS/IC with Hunner lesions. It starts as a standard RCT (n=80), but continues as an aggregated N-of-1 trial. There are three parallel arms, receiving blinded treatment for three periods (1 x/week for 6 weeks, ratio placebo to intervention in periods of 2:1). Followed by an open prospective part for the long-term efficacy. The primary study outcome is the maximum bladder pain experienced in the last 3 days measured using the visual analogue pain scale (0–10). This study is a collaboration with the Dutch government and will deliver evidence for the decision to reimburse the therapy. Furthermore, this multidesign study will allow us to compare the two main methods to evaluate applicability for future study designs for BPS/IC research. Ethics and dissemination Ethical approval was given by METC Oost-Nederland, file number: 2020-7265, NL-number: NL76290.091.20. Findings from this study will be disseminated via publication, reports and conference presentations. Trial registration number ClinicalTrials.gov identifier (NCT number): NCT05518864.


  • Open Access

    The functioning and the complication rate of extreme long existing urinary diversions

    by Charlotte J. Van Ginkel, Hanny Cobussen-Boekhorst, Frank Martens, Wout F.J. Feitz, John P.F.A. Heesakkers

    Purpose of review: This review is timely and relevant because many patients live many years with urinary diversions. Knowledge about the long term outcome with respect to function and complications are important for patient counseling and for the manner to follow-up patients. This study was performed to investigate the functioning of urinary diversions constructed > 25 years earlier. Recent findings: Most studies have a relatively shorter follow-up, mainly focussing on short term postoperative complications. Focussing on the long term, urinary tract infections (UTI) including pyelonephritis are common. Mild kidney function deterioration is described. Summary: Retrospective study (2018–2019); 43 patients with regular follow-up at the Radboud University Medical Centre Nijmegen the Netherlands. Ileal conduit (n = 19) and ureterosigmoidostomy (n = 11) are the most common diversion types for reasons such as: bladder exstrophy (n = 15), urinary incontinence (n = 9) and malignancy (n = 8). This series with a median follow-up of 40 years, shows it is possible to live and cope with a urinary diversion for a very long time. Ureterosigmoidostomies give relatively good results. Ileal conduits are functioning properly with acceptable complication rates. 95% suffers from chronic UTI's. Kidney function deterioration was mild. Diversions for benign reasons have more complex complications compared to diversion constructed for malignant reasons. Video http://links.lww.com/COU/A32.


  • Open Access

    Case report. Bacteriofagentherapie bij een cystoprostatitis

    by Charlotte J. van Ginkel, Rob J. A. M. Davits

    Samenvatting: Bacteriofagentherapie biedt mogelijk een oplossing voor de problemen van antibioticaresistentie. Ze werd toegepast in deze casus van een 71-jarige man met cystoprostatitis op basis van een multiresistente Klebsiella pneumoniae. De patiënt had sterk invaliderende klachten van nycturie en dysurie. Antibiotische behandeling hielp slechts tijdelijk. Behandeling met bacteriofagen, oraal en intravesicaal, resulteerde echter in afname van klachten, met tot nu toe blijvend succes. Het veilig gebruik met positieve resultaten van bacteriofagentherapie werd reeds beschreven in de (urologische) literatuur. De behandeling lijkt veelbelovend. Het opzetten van gerandomiseerde studies is nodig om te onderzoeken of deze therapie een oplossing kan zijn bij de problemen van de huidige toenemende antibioticaresistentie.